Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | STAT3 | P40763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20380617 | 0.91 | APP (0.33) | APPCYP2C9GRM2FFAR4CHEK1 | |
| SCHEMBL16325783 | 0.90 | APP (0.37) | APPCYP2C9GRM2P2RY1FFAR4 | |
| SCHEMBL16326155 | 0.90 | ALOX5AP (0.35) | APPCYP2C9GRM2P2RY1FFAR4 | |
| SCHEMBL12889493 | 0.89 | ALOX5AP (0.40) | APPCYP2C9GRM2P2RY1FFAR4 | |
| SCHEMBL12889466 | 0.89 | MMP12 (0.36) | GRM2FFAR4CHEK1MMP12TRPA1 | |
| SCHEMBL16325794 | 0.87 | ALOX5AP (0.33) | APPCYP2C9GRM2P2RY1CHEK1 | |
| SCHEMBL17365955 | 0.86 | MMP12 (0.31) | APPCYP2C9GRM2FFAR4MMP12 | |
| SCHEMBL20380742 | 0.86 | APP (0.32) | APPCYP2C9GRM2ALOX5APFEN1 | |
| SCHEMBL16325978 | 0.86 | ALOX5AP (0.38) | APPCYP2C9GRM2P2RY1FFAR4 | |
| SCHEMBL16325929 | 0.85 | MMP12 (0.35) | FFAR4MMP12TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023799-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023799-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | PIEZO1, ROCK1, RCC1 | APP 1099/4885CYP2C9 756/4885GRM2 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.